Rationale: Protein kinase (PK)Cs and calpain cysteine proteases are highly expressed in myocardium. Ischemia produces calcium overload that activates calpains and conventional PKCs. However, calpains can proteolytically process PKCs, and the potential in vivo consequences of this interaction are unknown.
R eceptor-mediated activation of protein kinase (PK)Cs via G␣q and phospholipase C signaling is implicated in myocardial contractile abnormalities, cardiac hypertrophy, and the progression to heart failure. 1, 2 Of the 12 recognized PKC isoenzymes, 3 myocardium expresses significant amounts of 4: 2 "conventional" isoenzymes (PKC␣ and PKC␤) and 2 "novel" isoenzymes (PKC␦ and PKC). PKC␣ is the most abundant PKC in mouse myocardium and is specifically implicated in cardiac hypertrophy, contractile dysfunction, and cardiomyopathy development. 4 -8 The canonical mechanism for PKC activation is via phospholipase C-mediated increases in cytosolic free calcium and phospholipids. Walsh and colleagues have suggested that oxidative stress can stimulate a pathway to PKC activation that is independent of these receptor-coupled signaling events, although specific mechanisms were not identified. 9 PKCs consist of an N-terminal regulatory domain connected to a C-terminal catalytic domain via an interdomain V3 "hinge" region. 10 In their inactive state, the N-terminal regulatory and C-terminal catalytic domains interact to sequester critical membrane targeting and substrate-binding domains. Conventional PKC isoenzymes, including PKC␣, are activated when calcium and phospholipid bind to specific domains within the N terminus and disrupt intramolecular bonding, thus unfolding the molecule and exposing C-terminal substrate binding domains. 11 Conventional wisdom holds that concomitant with PKC activation, calcium and phospholipid initiate PKC inactivation through calpain-mediated proteolysis. [12] [13] [14] Calpains are ubiquitous calcium-dependent cysteine proteases. 15 We previously detected low levels of calpain 1, but not calpain 2, proteolytic activity in nonstressed myocardium. 16 However, myocardial free calcium levels rise dramatically to 600 to 1000 nmol/L (depending on perfusate calcium concentration) during ischemia/reperfusion, 17 exceeding levels that induce calpain activation in cardiac myocytes. 18 For this reason, calpain-mediated degradation of myofilament proteins has been implicated in postischemic myocardial injury and stunning 19 -22 and in preload-induced proteolysis. 23 Calpain proteolysis of myocardial PKC␣ has not been examined. Here, we show that calpain 1 cleaves myocardial PKC␣ as a specific response to ischemia/reperfusion. We demonstrate that the C-terminal PKC␣ calpain cleavage fragment is a potent myocardial kinase. Finally, we determine that the PKC␣ C-terminal fragment, but not the N-terminal fragment, induces cardiomyopathic features, independent of myocardial ischemia or calpain activation.
Methods

Transgenic Mice
Mice conditionally overexpressing calpain 1 with a tetracyclinesuppressible ("tet-off") ␣-myosin heavy chain-driven conditional transgenic system have been described previously. 16 The present studies used the lower-expressing "L2" line with calpain induction at 8 weeks of age. This line of calpain 1 transgenic mice does not exhibit spontaneous proteolysis and does not develop a cardiac phenotype after transgene induction in adult hearts. Calpain 1 knockout mice were previously described. 24 Human PKC␣ and fragments encoding peptides corresponding to the calpain N-terminal cleavage fragment (PKC␣NT) and C-terminal cleavage fragment (PKC␣CT) were expressed using the same conditional cardiac-specific expression system. Invasive hemodynamic studies and M-mode echocardiography were performed using standard techniques. Isolated perfused mouse hearts underwent ex vivo ischemia/reperfusion injury as described. 25 Mice were housed and studied according to procedures approved by Animal Studies Committee of the Washington University School of Medicine.
Immunoblot Analysis
SDS-PAGE and immunoblotting used standard techniques. The following antibodies were used: anti-PKC␣ C terminus (Santa Cruz Biotechnology, sc-208; recognizes an epitope at the C terminus of human PKC␣), anti-PKC␣ (Santa Cruz Biotechnology, sc-80; recognizes an epitope within the N-terminal hinge region [residues 292 to 317] of human PKC␣), anti-MyBP-C3 (Santa Cruz Biotechnology, H-9), anti-annexin II (Santa Cruz Biotechnology, C-10), and anti-phosphoserine/threonine (Abcam, ab17464).
Phosphoproteome Profiling
Two-dimensional differential in-gel electrophoresis (DiGE) and protein identification by mass spectrometry (MS) were performed by Applied Biomics (Hayward, Calif). Mouse ventricular homogenates were labeled with Cy3 and Cy5 (CyDye, GE Healthcare), mixed, and resolved in the first dimension on a pH gradient of 3 to 10 (Pharmalytes, Sigma-Aldrich). Isoelectric focusing strips were transferred to 12% SDS-PAGE gels for resolving in the second dimension. Twodimensional gel phosphoprotein staining was carried out with ProQ diamond phosphoprotein staining kit (Invitrogen). Samples were visualized immediately following SDS-PAGE using a Typhoon TRIO laser scanner (GE Healthcare) and analyzed by Image QuantTL software (GE Healthcare). In-gel analysis and cross-gel analysis used DeCyder software version 6.5 (GE Healthcare). Each 2D experiment was performed on 2 individual hearts from each study group.
Protein spots of interest were chosen using an Ettan Spot Picker (Amersham BioSciences) and digested in-gel with modified porcine trypsin protease (Trypsin Gold, Promega). Tryptic peptides were desalted and concentrated on ZipTip C 18 (Millipore), eluted in 0.5 L of matrix solution (␣-cyano-4-hydroxycinnamic acid [5 mg/mL in 50% acetonitrile, 0.1% trifluoroacetic acid, 25 mmol/L ammonium bicarbonate]), and spotted on the MALDI plate (model ABI 01-192-6-AB). MALDI-TOF MS (matrix-assisted laser desorption/ionization-time-offlight MS) and TOF/TOF tandem MS/MS were performed on an ABI 4700 mass spectrometer (Applied Biosystems, Framingham, Mass). MALDI-TOF mass spectra were acquired in reflection positive ion mode, averaging 4000 laser shots per spectrum. TOF/TOF tandem MS fragmentation spectra were acquired for each sample, averaging 4000 laser shots per fragmentation spectrum on each of the 10 most abundant ions present in each sample (excluding trypsin autolytic peptides and other known background ions).
Peptide mass and associated fragmentation spectra were submitted to GPS Explorer workstation equipped with MASCOT search engine (Matrix science) to search the database of National Center for Biotechnology Information nonredundant (NCBI-nr). Searches were performed without constraining protein molecular weight or isoelectric point, with variable carbamidomethylation of cysteine and oxidation of methionine residues, and with 1 missed cleavage also allowed in the search parameters. Candidates with either a protein score confidence interval percentage or ion confidence interval percentage of Ͼ95% were considered significant.
Statistical Methods
All results are presented as meansϮSEM. Paired group analysis used Student's t test. Multiple groups were compared by one-way ANOVA and Tukey's post hoc test. PϽ0.05 was considered significant.
Results
Ischemia Stimulates Calpain 1-Mediated Limited Proteolysis of Myocardial PKC␣
In the process of assessing PKC activation by cardiac ischemia/ reperfusion, we observed formation of a single Ϸ40-kDa PKC␣ cleavage product after 1 hour of reperfusion in normal hearts, but not calpain 1 knockout hearts ( Figure 1A ). This result suggested that PKC␣ is a substrate for proteolysis by calpains 26, 27 activated after myocardial ischemia, Accordingly, we performed in vitro studies to define the products of calpain 1-mediated PKC␣ proteolysis. Calpain 1 cleaved PKC␣ into two ϳ40-kDa fragments in a manner that was time-and concentration-dependent ( Figure 1B , top and lower left). Ex vivo proteolysis of myocardial PKC␣ required addition of calcium ( Figure 1B, lower right) .
We took advantage of previously described cardiac transgenic mice expressing calpain 1 or the calpain inhibitor protein calpastatin (CSTN), 16 to examine the consequences of cardiomyocyte calpain 1 activation or inhibition on PKC␣ fragmentation in ischemic hearts. The Ϸ40-kDa PKC␣ fragment was detected only in ischemia-reperfused calpain 1 hearts ( Figure  1C , left); characteristic calpain-mediated proteolysis of troponin I and T was also observed ( Figure 1C, left) . 20, 28 No such fragmentation was detected in identically treated CSTN hearts ( Figure 1C, right) . Thus, ischemia/reperfusion induces calpain 1-mediated fragmentation of myocardial PKC␣. 
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Calpain 1 Increases Postinfarction Myocardial Damage
To determine the functional consequences of calpain activation ischemic myocardium, we measured infarct size and outcomes after coronary ligation of conditional calpain 1 transgenic (FVB/N background) and calpain knockout mice (C57 background). (Calpastatin transgenic mice develop an aggresomal cardiomyopathy that confounds infarction studies. 16 ) Infarct size at 24 hours was increased by approximately one-third in calpain 1-expressing mice (Figure 2A ), and early survival was strikingly decreased ( Figure 2B ). We used fluorescent TUNEL staining to assess cardiac myocyte death in the noninfarct myocardium, which was increased Ϸ50% ( Figure 2C ). The reciprocal experiment with calpain 1 knockout mice gave the opposite result. Although strain differences resulted different absolute infarct sizes between the overexpression and knockout studies, calpain 1 knockout mice showed no difference in postinfarction mortality (not shown), had a modest reduction in infarct size measured 4 days after coronary occlusion ( Figure 2D ), and had better isovolumic systolic and diastolic function ( Figure 2E ) compared with identically treated wild-type C57 controls. Together, these studies show that calpain activation in ischemic myocardium contributes to adverse outcomes and raised the possibility that calpain cleavage of PKC␣ plays a contributory role.
Calpain 1 Cleaves PKC␣ at Multiple Sites Within the V3 Hinge Region
In mouse hearts, PKC␣ impairs ␤-adrenergic receptor responsiveness, depresses contractility, and predisposes to heart failure. 4, 5 In this context, we considered that there were 2 possible consequences of calpain-mediated PKC␣ fragmentation. First, calpains might "rescue" the PKC␣ phenotype by degrading and inactivating PKC␣. [12] [13] [14] 29 Alternatively, calpain proteolysis might produce novel biological effects through independent activity of the fragments. 26 To evaluate the latter possibility, it was necessary to define the daughter fragments by identifying the calpain cleavage site(s). Nishizuka and colleagues group reported putative calpain cleavage sites between amino acids K316 and V317 and between R324 and K325. 26 Therefore, we initially mutated human PKC␣ V317 and K325 to prolines but found no effect on proteolysis by calpain 1 ( Figure 3A ). We next substituted alanines for K316 and V317 or R324 and K325 (in pairs), but these mutations also did not eliminate calpain 1-mediated PKC␣ cleavage ( Figure 3A ). Likewise, simultaneous mutation of all 4 amino acids failed to prevent calpain cleavage ( Figure 3A ). These results suggest that that the predictions of Nishizuka and colleagues are overly restrictive.
Another view is that calpains recognize any of several undecapeptides in their targets and cleave at variable positions relative to these domains. 30 Accordingly, we performed alanine substitution mutagenesis of the 2 halves of the PKC␣ V3 hinge region, en bloc, and also generated a mutant that included both alanine cassettes (double cassette). Purified calpain-1 was able to cleave both the PKC␣ cassette 1 and cassette 2 mutants, but not the double cassette mutant ( Figure 3B ). Together, these studies reveal promiscuity of calpain 1 proteolysis within the PKC␣ V3 hinge domain but exclude calpain 1 cleavage sites outside of the V3 region of PKC␣. Thus, any calpain 1-mediated PKC␣ cleavage events will separate intact N-terminal regulatory and C-terminal catalytic kinase fragments.
PKC␣ N-and C-Terminal Fragments Translocate to Different Subcellular Domains
We examined the subcellular distribution of PKC␣ peptides corresponding to the calpain cleavage fragments after transient transfection in HEK293 fibroblasts. Full-length PKC␣ was primarily cytosolic in serum-deprived cells but translocated to cell membranes after treatment with 100 nmol/L phorbol myristate acetate (PMA) ( Figure 4A ). The N-terminal PKC␣ peptide (PKC␣-NT) appeared in a punctate distribution primarily in the cytosol and showed no translocation after PMA, whereas the C-terminal peptide (PKC␣-CT) showed a groundglass cytosolic appearance in unstimulated cells and translocated to cell membranes after PMA ( Figure 4A ).
The N-terminal and C-terminal domains of PKCs are tethered via intramolecular hydrogen bonds. 10 We tested whether the free N-and C-terminal peptides interacted, which might have functional implications, by cotransfecting them in HEK293 cells, labeling them with different fluorophores, and performing confocal microscopy at baseline and after PMA treatment. Although PKC␣-NT and -CT were cytosolic in unstimulated cells, they did not colocalize ( Figure 4B , merged image). After PMA treatment, the 2 peptides were distributed in 
PKC␣ Fragments Are Stable in Myocardium and Have Functional Consequences
Having determined that calpain cleavage of PKC␣ separates the protein into 2 approximately equal-sized N-terminal and C-terminal halves, we next considered that any biological function of the fragments depended first on whether they were retained in cardiac myocytes. As this is an area of some controversy 27, 31 we directly addressed the issue by conditionally expressing the 2 PKC␣ calpain fragmentation products and their parent, full-length PKC␣, in mouse hearts.
Because a cardiac-specific (nonconditional) PKC␣ transgenic mouse was previously described, 5 and has a phenotype similar to our conditional PKC␣ transgenic (see below), we propagated and fully phenotyped a single conditional fulllength PKC␣ mouse line. Three independent lines of conditional PKC␣ N-terminal fragment (PKC␣NT) and four lines of conditional PKC␣ C-terminal fragment (PKC␣CT) mice were crossed to the tet-regulator transgene line, as required for protein expression. 32 Of these, 2 lines of each were selected for phenotypic analysis based on initial studies showing levels of transgenic protein expression that were roughly equivalent to those of our full-length PKC␣ mouse (Online Figure I and Online Table I , available in the Online Data Supplement at http://circres.ahajournals.org). Fulllength PKC␣ expressed at Ϸ8-fold endogenous levels ( Figure  5A ) produced mice with dilated ( Figure 5B ) and hypocontractile ( Figure 5C and 5E) hearts, having greatly diminished ␤-adrenergic responsiveness ( Figure 5D ). This phenotype is similar to that previously described for both intrinsic cardiac PKC␣ activation 4 and Ϸ5-fold constitutive MYH6-driven cardiac PKC␣ overexpression. 5 Expression of PKC␣NT at levels similar to full-length PKC␣ ( Figure 5A ) had no impact on cardiac size ( Figure 5C ) or ejection performance ( Figure 5C and 5E), although adrenergic responsiveness was slightly diminished ( Figure 5D ). Remarkably, and despite expression levels lower than those for fulllength PKC␣ or PKC␣NT ( Figure 5A ), PKC␣CT induced massive biventricular dilation ( Figure 5B and Figure 5E , right) and severely depressed ejection performance ( Figure 5C ). Furthermore, the characteristic ␤-adrenergic unresponsiveness seen with cardiomyocyte-autonomous PKC␣ activation ( Figure 5D and elsewhere 4, 5 ) was fully recapitulated in PKC␣CT transgenic mice ( Figure 5D ). These results demonstrate that both the N-terminal and C-terminal peptides corresponding to PKC␣ calpain proteolytic fragments are retained in cardiac myocytes and that the C-terminal fragment of PKC␣ (but not the N-terminal fragment) produces a cardiac phenotype similar to, but more severe than, parent PKC␣.
The C-Terminal Fragment of PKC␣ Is a Dysregulated Myocardial Serine/Threonine Kinase
In vitro studies have suggested that C-terminal calpain cleavage fragments of some PKCs can act as unregulated and constitutively active kinases. 27 To determine whether the PKC␣ C-terminal peptide exhibited kinase activity, we used DiGE and ProQ phosphoprotein staining. Nontransgenic mouse myocardium exhibits a characteristic phosphoprotein pattern (Figure 6, red) . PKC␣NT myocardium showed a similar phosphoprotein pattern (see below and data not shown). In contrast, PKC␣ transgenic myocardium exhibited a number of newly phosphorylated proteins ( Figure 6 , green), virtually all of which were also observed in PKC␣CT myocardium (Figure 6 , blue). PKC␣CT myocardium was similar to PKC␣ but additionally revealed phosphopeptides that were increased in staining intensity from, or not observed at all in, full-length PKC␣ hearts (blue spots in Figure 6 , merged).
These data suggested that cardiomyocyte-expressed PKC␣CT possesses kinase activity that mimics that of its parent PKC␣ but may also be partly dysregulated and/or mistargeted. To identify differentially phosphorylated proteins, we selected several spots of interest and identified them by mass spectroscopy (Online Table II ). Two phosphoprotein spots that were more prominent in PKC␣ transgenic than control hearts (arrowheads, Figure 6 ) were identified as heat shock protein 90 (HSP90␤) and phosphoglucomutase, which are serine/threonine-phosphorylated in striated muscle. 33 MyBP-C, ␣ cardiac actin, and the regulatory subunit of protein phosphatase 2a (PP2A pR65) were each phosphorylated by both full-length and the C-terminal fragment of PKC␣, whereas ␣-actinin, annexin II, and calsarcin 1 (myozenin-1) appeared to be phosphorylated only in PKC␣CT hearts.
PKCs are serine/threonine kinases, and the ProQ phosphoprotein staining procedure we used to map and quantify protein phosphorylation by 2D gel electrophoresis does not distinguish between serine/threonine phosphorylation and tyrosine phosphorylation. Therefore, we also performed 2D immunoblotting using an anti-phosphoserine/threonine antibody. The protein pattern was consistent between myocardial samples ( Figure 7A , green), but differences in anti-phosphoserine/threonine immunoreactivity were revealing. Compared with nontransgenic controls, PKC␣NT serine phosphorylation was similar. In contrast, serine/threonine phosphorylation was generally increased in PKC␣ and PKC␣CT myocardium (Figure 7, red) , reproducing the findings from phosphoprotein staining. Thus, observed differences in protein phosphorylation in PKC␣ and PKC␣CT hearts compared with control and PKC␣NT hearts are attributable to increased serine/threonine phosphorylation.
The C-Terminal Fragment of PKC␣ Abnormally Phosphorylates MyBP-C
Collectively, the above data indicate that cardiac ischemia can activate PKC␣-like activity by calpain-mediated formation of the free PKC␣ C-terminal fragment. The exaggerated phenotype and phosphoprotein profile of PKC␣CT hearts further suggested that PKC␣CT might have effects beyond those of activityconstrained intact PKC␣. We pursued evidence to support this idea by comparing phosphorylation of myosin binding protein C (which mass spectroscopy had identified as differentially phosphorylated; see Figure 6 and Online Table II) in PKC␣ and PKC␣CT hearts. MyBP-C is a polyphosphorylated substrate of at least 3 kinases, PKC, calmodulin kinase II, and PKA, 34 and increased MyBP-C phosphorylation contributes to postischemic myocardial dysfunction. 35 We first confirmed the mass spectroscopic identity and differential phosphorylation of MyBP-C by 2D immunoblotting ( Figure 8A ). Next, we repeated the DiGE studies using a narrower pH gradient for better protein separation. MyBP-C migrated as 9 spots on the 2D gels ( Figure 8B ), and the protein profile was shifted toward a lower pH in PKC␣CT hearts ( Figure 8B ). ProQ staining confirmed that this shift reflected increased MyBP-C phosphorylation ( Figure 8B, bottom) . Phosphorylation mapping of canine MyPBC3 has indicated previously that the 2 most basic spots are nonphosphorylated MyBP-C, spots 3 to 5 are MyBP-C-phosphorylated at S282, and spots 6 to 9 represent various combinations of polyphosphorylated MyBP-C at S273, S282, S284, S302, and S307 (mouse amino acid numbering). 35 Analysis of individual spots also suggested that the polyphosphorylated MyBP-C species were increased in PKC␣CT hearts ( Figure 8C ), and this was confirmed by phospho-MyBP-C-specific immunoblotting ( Figure  8D ). Thus, PKC␣CT phosphorylation of MyBP-C was greater than that of intact PKC␣, suggesting promiscuous activity of the free catalytic fragment.
Discussion
PKC family members are activated as part of many neurohormone receptor signaling pathways linked to cardiac disease. Here, we report that limited calpain 1-mediated proteolytic cleavage of PKC␣ during ischemia generates a catalytically active kinase fragment, independent of conventional receptor pathways. PKC␣ proteolysis was detected only after ischemia/ reperfusion in either normal or calpain 1 transgenic hearts, demonstrating a requirement for ischemia that presumably activates calpain via increased free calcium. Through conditional overexpression of the predicted calpain PKC␣ proteolysis products, we showed that both the N-and C-terminal PKC␣ calpain fragments are retained in the myocardium. The N-terminal fragment exhibited no kinase activity, had no effect on baseline cardiac structure and contractile performance, and had only a modest negative impact on ␤-adrenergic responsiveness. In contrast, the C-terminal PKC␣ fragment exhibited broad kinase activity and was a potent negative regulator of myocardial function, independent of ischemia or calpain activation. The extent of myocardial protein phosphorylation and the deleterious cardiac consequences of the free PKC␣ catalytic fragment were all greater than those of PKC␣ itself.
The present findings invert the accepted paradigm for PKC activation/inactivation. Classically, agonist stimulation of Gqcoupled neurohormone receptors activates phospholipase C that promotes the hydrolysis of phosphatidylinositol bisphosphate to sn-1,2-diacylglycerol (DAG) and inositol(1,4,5)trisphosphate (IP 3 ). The latter activates IP 3 receptors to stimulate release of calcium from endoplasmic and sarcoplasmic reticulum. Calcium and DAG bind to specific sites in the N-terminal regulatory domain of conventional PKCs, altering their structures and weakening intramolecular bonds that hold the N-and C-terminal halves together like 2 halves of a clam shell. Consequently, the PKC protein unfolds at the intervening hinge domain. Physical separation of N-terminal regulatory domains from their C-terminal substrate-binding and membrane-targeting (RACKbinding) domains disinhibits the kinase, permitting membrane translocation and substrate phosphorylation. This process not only activates PKC but also begins the process for its inactivation through proteolytic degradation. Indeed, before the development of specific pharmacological inhibitors, PKC downregulation by prolonged exposure to phorbol ester DAG mimetics was commonly used for in vitro studies. 36 Notwithstanding that calpains are widely known as effectors of PKC inactivation through degradation, 12, 37 this is opposite to the effect that we observed. Whereas parental myocardial PKC␣ can certainly be removed by the proteolytic actions of calpain, we found that calpain 1 produced a catalytically active daughter PKC␣ fragment corresponding to the PKM␣ of Nishizuka and colleagues. 26 Thus, the mechanism for PKC "inactivation by proteolytic degradation" actually increases pathological signaling by producing a kinase that is not subject to normal physiological constraints.
PKC␣ is upregulated Ϸ80% in human and experimental cardiac hypertrophy, which contributes to impaired ␤-adrenergic signaling. 38, 39 Increased expression or activity of myocardial PKC␣ produces contractile dysfunction and cardiomyopathy phenotypes, 4,5 whereas its genetic ablation or pharmacological inhibition enhances contractility and protects against cardiomyopathy. [5] [6] [7] Although PKC-mediated phosphorylation of titin may regulate myocardial stiffness, 40 and it may exert an indirect effect of on phospholamban/SERCA function through phosphorylation of protein phosphatase inhibitor 1, 5 the myocardial substrates of PKC␣ are largely unknown and the mechanisms by which it causes cardiomyopathy are poorly understood. The present studies begin the process of identifying in vivo cardiac PKC␣ substrates and further indicate that the PKC␣ C-terminal fragment has a broader kinase substrate profile than the parent enzyme.
All of the phosphoproteins we identified (or their skeletal muscle counterparts) have previously been detected in the human muscle phosphoproteome and are known to be phosphorylated on one or more serine/threonine residues. 33 Our studies showed that full-length PKC␣ and the free PKC␣ C-terminal fragment phosphorylated many of the same cardiac substrates; the chaperone HSP90␤ is an example. However, we identified 2 catalytic effects that functionally distinguish the C-terminal fragment from full-length PKC␣. The first is hyperphosphorylation of normal PKC␣ substrates. This was specifically demonstrated for the myosin binding protein MyBP-C, which showed a stepwise increase in phosphorylation from control hearts, to those expressing PKC␣, to those expressing PKC␣CT. It is of special interest that a MyBP-C hyperphosphorylation pattern similar to ours is seen after myocardial ischemia and is prevented by ischemic preconditioning. 35 MyBP-C phosphorylation by PKC was also recently proposed as contributing to dilated cardiomyopathy. 41 Thus, MyBP-C is one potential mediator of cardiomyopathic effects of PKC␣CT.
The second distinct effect of PKC␣CT was phosphorylation of proteins that were not usual substrates for full-length PKC␣, such as the cytoskeletal protein ␣-actinin. Indeed, PKC does not normally phosphorylate ␣-actinin, 42 although PKN, a Rho-activated serine/threonine kinase having a catalytic domain similar to the PKCs (and therefore to the PKC␣ C-terminal fragment), does. 43 Excessive phosphorylation of normal substrates and phosphorylation of atypical substrates are the expected consequences of a catalytic kinase lacking normal regulatory and targeting domains.
Calpain-mediated proteolytic cleavage of PKCs into PKMs was described years ago, 26 but the physiological relevance of these events for in vivo cell signaling has been discounted because of the presumed instability of the proteolytic frag- ments. 31 Indeed, PKM produced via the actions of calpain 2 is highly unstable, whereas that produced by calpain 1 can persist even after complete PKC degradation. 27 Recent studies of PKM production in PKC-rich neural tissue have stimulated interest in the possibility that calpain cleavage regulates PKC signaling in learning and memory. 44, 45 The mollusk Aplysia exhibits calpaindependent proteolysis of PKC and generation of persistently active PKM that is essential for intermediate memory. 46 In these studies, pharmacological PKC inhibitors that targeted the catalytic domain of PKC prevented the PKM effect (intermediateterm memory), whereas the PKC inhibitor, calphostin C, which interacts with the regulatory domain, was ineffective. Because intermediate-term memory is a sustained response, these findings suggest special importance for generation of the constitutively active catalytic PKM fragment for prolonged signaling. Similar findings were recently described in rat brain, where calcium influx through voltage-dependent calcium channels generated PKM that produced agonist-independent burst firing of dopamine cells. 47 Again, this response was inhibited by chelerythrine, which acts at the PKC catalytic domain, but not by calphostin C, which acts on the DAG binding site of the regulatory domain.
The intersection of PKC and calpain activation in calciumoverloaded ischemic tissue represents the convergence of 2 potent signaling pathways. Myocardium may be especially sensitive to PKC-calpain functional interactions, because the heart is adversely impacted by PKC␣ signaling 4,5 and contains abundant calpain 1 that is activated during ischemia. 16 The intent of our studies was to determine whether calpainmediated processing of PKC␣ occurs in ischemic hearts, to ascertain how this affected myocardial kinase activity, and to assess the possible consequences of this novel signaling event on the heart. Thus, the extent to which calpain-mediated PKC␣ cleavage contributes to postischemic myocardial dysfunction and progression to heart failure is unknown at this time. However, because PKC␣ is the most abundant PKC isoform in myocardium, 4 calpain 1 is activated and upregulated following myocardial ischemia, 48 -50 and the PKC␣ C-terminal peptide can clearly be retained for significant periods in myocardium, it is likely that calpain-generated PKM␣ is detrimental to the postischemic heart. The present observations may have relevance to ongoing evaluations of therapeutics designed to inhibit cardiac PKC␣ signaling. Catalytically active PKM␣ generated by calpains activated during ischemia/reperfusion will not be sensitive to PKC␣ inhibitors, such as calphostin C, that target regulatory domains. 46, 47 Our understanding is that PKC␣ inhibitors currently being evaluated in heart failure, such as Ro-32-0432 and R0 -31-8220, act at the catalytic site. Their reported benefits may therefore accrue, in part, from PKM␣ inhibition. 6 
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Novelty and Significance
What Is Known?
• Protein kinase (PK)C signaling is activated by neurohormonal G protein-coupled receptor pathways stimulated during cardiac stress and is detrimental to heart function.
• Calpain cysteine proteases are activated by calcium released from the myocardium damaged by ischemia, and they injure the heart by actively degrading myocardial proteins.
What New Information Does This Article Contribute?
• We have identified and characterized the crosstalk between the calpain and PKC stress response pathways, providing for receptorindependent activation of cardiac PKC␣ signaling.
• Cleavage of PKC␣ by calpain 1, specifically in ischemic hearts, produces a catalytically active kinase fragment that, because of the proteolytic removal of its normal regulatory domains, is not subject to usual physiological constraints.
• The unregulated catalytic fragment exhibits promiscuous kinase activity and exerts detrimental effects on heart structure and function greater than those of its parent, PKC␣.
Calpains and PKC are both calcium-activated stress signaling pathways that independently affect cardiac function; however, the implications of their potential interaction had not been explored. Calpains typically degrade substrate proteins. We identified multiple adjacent calpain cleavage sites in PKC␣ that, rather than degrading the kinase, liberate a catalytically active fragment that is unregulated and mistargeted, exhibiting promiscuity of substrate phosphorylation. These findings describe a receptor-independent mechanism that activates a potent PKCderived rogue kinase. The calpain-generated PKC␣ catalytic fragment is only observed after ischemic injury, is stable in the myocardium, induces hyperphosphorylation of normal PKC␣ substrates and misdirected phosphorylation of nonsubstrate proteins, and produces aggressive cardiomyopathy. Our results have implications for cardiac therapeutics. They suggest that inhibiting PKC signaling at the level of neurohormone receptors or calcium activation is unlikely to affect the calpain-PKC pathway; instead, direct suppression of PKC catalytic activity might be a more effective therapeutic approach.
